FOXP3 and non-small cell lung carcinoma: miR-532-3p inhibits nonsmall cell lung cancer (NSCLC) via forkhead Box P3 (FOXP3), suggesting that the miR-532-3p/FOXP3 axis could be a potential therapeutic target12.